2022-09-05-港交所-同仁堂科技_二零二二年中期报告_41页_5mb

Financial Performance Overview

• Revenue for the first half of 2022 reached RMB 301.47 billion, marking an 8.99% increase from the same period in 2021.
• Net profit attributable to owners was RMB 318.32 million, showing a slight growth of 0.91%.
• Earnings per share remained unchanged at RMB 0.25.
• The Board recommended no interim dividend distribution, consistent with the previous year.

Key Business Insights

• Despite COVID-19 challenges, the company implemented strategies such as closed-loop production and resource allocation for key products to maintain supply and sales stability.
• Product performance varied; notable increases were seen in items like Jia Wei Xiaoyao Wan (66% growth) and Sangye Gan'er Wan, while others like cold medicine faced slight declines.
• Subsidiaries, including Tongrentang Guoyao, encountered production disruptions but showed recovery in international markets, contributing to overall resilience.

Main Highlights and Challenges

• Financial health indicators, such as a low capital liability ratio and strong liquidity metrics (e.g., current ratio and quick ratio improving solvency), demonstrate robust financial position despite market headwinds.
• Research and development investments rose, focusing on existing products to enhance competitiveness.
• Future outlook remains positive with planned expansion in OTC markets and continued emphasis on large-volume product strategies to drive sustained growth.